A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2 Completed 103 enrolled Carmot Therapeutics, Inc. Hoffmann-La Roche · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).

Timeline

Start: 2022-02-22
Primary completion: 2023-02-28
Completion: 2023-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CT-868	Unknown	1.75 mg	Subcutaneous
Subject	CT-868	Unknown	4 mg	Subcutaneous

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications